Gil M Labrucherie Nektar Therapeutics (NKTR) insider trading activity

Gil M Labrucherie is SVP, COO & CFO of NEKTAR THERAPEUTICS. Currently has a direct ownership of 312,905 shares of NKTR, which is worth approximately $403,647. The most recent transaction as insider was on May 16, 2022, when has been sold 17,448 shares (Common Stock) at a price of $3.95 per share, resulting in proceeds of $68,920. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 313K

0% 3M change

0% 12M change

Total Value Held $403,647

Gil M Labrucherie Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 16 2022	SELL Open market or private sale	$68,920 $3.95 p/Share	17,448 Reduced 5.28%	312,905 Common Stock
May 15 2022	BUY Grant, award, or other acquisition	-	28,750 Added 8.01%	330,353 Common Stock
Feb 16 2022	SELL Open market or private sale	$82,990 $10.95 p/Share	7,579 Reduced 2.45%	301,603 Common Stock
Dec 16 2021	BUY Grant, award, or other acquisition	-	52,950 Added 14.62%	309,182 Common Stock
Nov 18 2021	SELL Open market or private sale	$38,070 $12.69 p/Share	3,000 Reduced 1.16%	256,682 Common Stock
Nov 16 2021	SELL Open market or private sale	$278,321 $13.16 p/Share	21,149 Reduced 7.53%	259,682 Common Stock
Nov 15 2021	BUY Grant, award, or other acquisition	-	40,150 Added 12.51%	280,831 Common Stock

Aug 17 2021	SELL Open market or private sale	$40,680 $13.56 p/Share	3,000 Reduced 1.23%	240,231 Common Stock
Aug 16 2021	SELL Open market or private sale	$108,801 $13.83 p/Share	7,867 Reduced 3.13%	243,231 Common Stock
May 17 2021	SELL Open market or private sale	$144,533 $18.3 p/Share	7,898 Reduced 3.05%	251,098 Common Stock
Feb 16 2021	SELL Open market or private sale	$178,445 $22.37 p/Share	7,977 Reduced 2.99%	258,996 Common Stock
Feb 04 2021	SELL Open market or private sale	$990,500 $19.81 p/Share	50,000 Reduced 15.77%	266,973 Common Stock
Feb 04 2021	BUY Exercise of conversion of derivative security	$440,000 $8.8 p/Share	50,000 Added 13.62%	316,973 Common Stock
Feb 03 2021	SELL Open market or private sale	$980,500 $19.61 p/Share	50,000 Reduced 15.77%	266,973 Common Stock
Feb 03 2021	BUY Exercise of conversion of derivative security	$440,000 $8.8 p/Share	50,000 Added 13.62%	316,973 Common Stock
Feb 02 2021	SELL Open market or private sale	$1,043,000 $20.86 p/Share	50,000 Reduced 15.77%	266,973 Common Stock
Feb 02 2021	BUY Exercise of conversion of derivative security	$440,000 $8.8 p/Share	50,000 Added 13.62%	316,973 Common Stock
Dec 18 2020	BUY Grant, award, or other acquisition	-	40,000 Added 13.03%	266,973 Common Stock
Nov 16 2020	SELL Open market or private sale	$140,113 $16.93 p/Share	8,276 Reduced 3.52%	226,973 Common Stock

Also insider at

RZLT

Rezolute, Inc. Healthcare

SLRN

ACELYRIN, Inc.

CFO and CBO

GML